Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ Bcl-2ÀÇ ¹ßÇö¾ç»ó ¹× ´Ù¸¥ ¿¹ÈÄÀÎÀÚµé°úÀÇ °ü°è Status of Bcl-2 Expression and Its Relationship to the Other Prognostic Factors in Breast Cancer

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 6È£ p.1131 ~ 1139
¼Ò¼Ó »ó¼¼Á¤º¸
³ë°Ç¿µ ½Åµ¿ÇÏ/¹Ú¿ë·¡/½ÅÁØÈ£/±èÈï´ë/±è¿ë½Å/ÇÑ¿ø°ï/±èÁÖ¼·/±è¸í¼÷

Abstract

¼­·Ð
À¯¹æ¾ÏÀÇ ¿¹ÈÄ¿Í ¿¬°üµÇ¾îÀÖ´Â ÀÎÀÚµé·Î¼­ ¾×¿ÍÀÓÆÄÀý ÀüÀÌ¿©ºÎ, Á¾¾çÀÇ Å©±â, Á¾¾çÀÇ Á¶
Á÷ºÐÈ­µµ, È£¸£¸ó ¼ö¿ëü À¯¹«, ploidy¿Í S-phase fraction µîÀº ¸ðµÎ Àß ¾Ë·ÁÁø ¿¹ÈÄÀÎÀÚµé
ÀÌ´Ù. ÃÖ±Ù ºÐÀÚ»ý¹°Çаú À¯ÀüÇÐ µîÀÇ ¹ß´Þ·Î À¯¹æ¾Ï¿¡¼­ ¼¼Æ÷ÀÇ ¾ÏÀ¯ÀüÀÚÁõÆø, Á¾¾ç¾ïÁ¦À¯
ÀüÀÚÀÇ ¼Ò½ÇÀ̳ª º¯ÀÌ µîÀÌ ÈçÈ÷ °üÂûµÇ°í ÀÖ´Ù.
ÃÖ±Ù ¼¼Æ÷ÀÚ¸ê»ç(apoptosis)ÀÇ °úÁ¤À» Á¶ÀýÇϴµ¥ °ü¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø »õ·Î¿î ¹üÁÖÀÇ
À¯ÀüÀÚµéÁßÀÇ Çϳª·Î bcl-2 proto-oncogeneÀÌ Æ÷ÇԵǴµ¥ ÀÌ°ÍÀº ¼ºÀåÀÎÀÚÀÇ ¼Ò½Ç, ¾ß»ýÇü
p53 ´Ü¹é, Ç×¾ÏÁ¦, ¹æ»ç¼± µî¿¡ ÀÇÇØ À¯¹ßµÇ¾î ¼¼Æ÷ÀÚ¸ê»ç¸¦ ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ®ÀÖ´Ù.
bel-2 proto-oncogeneÀº ¿©Æ÷¼º¸²ÇÁÁ¾¿¡¼­ t(14;18)ÀÇ cloningÀ¸·Î ¹ß°ßµÇ¾úÀ¸¸ç, À¯ÀüÀÚ Àü
¼Û½ÇÇè¿¡ ÀÇÇØ ¼ºÀåÀÎÀÚ°¡ ¼Ò½ÇµÈ Á¶Ç÷¼¼Æ÷±º°ú Çâ½Å°æ¼ºÀÎÀÚ ¼Ò½Ç ½Å°æ¿¡¼­ ¼¼Æ÷ÀÚ¸ê»ç¸¦
¹æÇØÇÏ´Â Bcl-2ÀÇ ¿ªÇÒÀÌ Áõ¸íµÇ¾ú´Ù. µ¿¹°½ÇÇè¿¡¼­ Bcl-2´Â ¼¼Æ÷ÀÇ »ýÁ¸À» ¿¬Àå½ÃÄ×°í, ½Ã
Çè°ü½ÇÇè¿¡¼­ bel-2 À¯ÀüÀÚ ¹ßÇöÀ» ¹æÇØÇÑ °á°ú ¹éÇ÷º´¼¼Æ÷ÀÇ ¼ºÀå°ú »ýÁ¸ÀÌ °¨¼ÒµÇ¾ú´Ù.
1990³â HockenberryµîÀº Bcl-2¸¦ ¼¼Æ÷ÀÇ Áõ½Ä¾øÀÌ ¼¼Æ÷ÀÚ¸ê»ç¸¦ ¸·´Â À¯ÀÏÇÑ
photo-oncogeneÀ¸·Î¼­ ¾ÏÀ¯ÀüÀÚÀÇ »õ·Î¿î ¹üÁÖÀÇ Çϳª·Î °á·ÐÁö¾ú´Ù.
T(14;18) ¿°»öü ÀüÀ§´Â bel-2 À¯ÀüÀÚ¸¦ ¸é¿ª±Û·ÎºÒ¸° Heavy chain°ú ³ª¶õÈ÷ ³õ¾Æ Bcl-2
´Ü¹éÀÇ °ú¹ßÇöÀ» ¾ß±â½ÃŲ´Ù. Bcl-2 ´Ü¹éÀº ¹ÌÅäÄܵ帮¾Æ ³»¸·, ÇÙ¸·, ¼ÒÆ÷ü¿¡ À§Ä¡Çϸç, Á¤
È®ÇÑ »ý¹°È­ÇÐÀû ÀÛ¿ë±âÀüÀº ¸ð¸£Áö¸¸, ¾Æ¸¶ GTP°áÇմܹéÀ¸·Î½á ¼ºÀåÀÎÀÚ ¼ö¿ëü ¸Å°³ ½Å
È£ Àü´Þ°æ·Î¿¡¼­ ±¤¹üÀ§ÇÑ ¿ªÇÒÀ» ÇÏ¿© ¼¼Æ÷¼ºÀå°ú ¼¼Æ÷ºÐ¿­, Á¶Á÷ Ç׻󼺰ú ÇüŹ߻ý¿¡¼­
Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ°ÍÀ¸·Î ÃßÁ¤µÈ´Ù. Bcl-2 ´Ü¹éÀº ¾ËÆÄ(26 KDa)³ª º£Å¸(22 KDa)ÇüÀ¸·Î Ç¥Çö
µÉ¼ö ÀÖ°í, ÀÌÁß Bcl-2 ¾ËÆÄ ´Ü¹éÀº Ç×»êȭȸ·Î¿¡ °ü¿©Çϸç, ÀÌ·¯ÇÑ Bcl-2ÀÇ °ú¹ßÇöÀº ¼¼Æ÷
ÀÚ¸ê»çÀÇ °úÁ¤À» ¹æÇØÇÏ¿© ¼¼Æ÷ÀÇ »ýÁ¸·ÂÀ» Áõ°¡½ÃÅ´À¸·Î½á Á¾¾ç¼¼Æ÷ÀÇ Å¬·Ð¼ºÆØâ¿¡ ±â¿©
ÇÏ°Ô µÈ´Ù.
Bcl-2 ´Ü¹éÀº »óÇǼ¼Æ÷¿Í ¾Ï¼¼Æ÷¿¡¼­µµ ¹ß°ßµÇ´Âµ¥ Bcl-2 ¾ç¼ºÀÎ ¼¼Æ÷´Â ±ä »ýÁ¸±â°£À»
°¡Áø´Ù. ÀÌ ¼¼Æ÷µéÀº È£¸£¸ó Á¶ÀýÇÏ¿¡ ÀÖ°í, bel-2 À¯ÀüÀÚÀÇ ¹ßÇöÀº ÀÚ±Ã, Á¤»óÀ¯¹æ ¹× À¯¹æ
¾ÏÀ» Æ÷ÇÔÇÑ È£¸£¸ó ¹ÝÀÀ¼º Á¶Á÷ÀÇ ³»ºÐºñ °¨¼ö¼º°ú ¿¬°üÀÌ ÀÖ´Â °ÍÀ¸·Î »ý°¢Åñ´Ù. Bcl-2´Ü
¹éÀÇ °ú¹ßÇöÀº ¼¼Æ÷ÀÇ »ýÁ¸±â°£À» ¿¬Àå½ÃÅ´À¸·Î½á È£¸£¸ó ÀÇÁ¸¼ºÀÇ »ó½Ç°ú °°Àº À¯ÀüÀû ÀÌ
»óÀÇ ±âȸ¸¦ Áõ°¡½ÃÅ°°Ô µÇ°í, ÀÌ·± °üÁ¡¿¡¼­ º¼ ¶§ Àü¸³¼±¾Ï¿¡¼­ Bcl-2 ´Ü¹éÀÇ °ú¹ßÇö°ú
¾Èµå·Î°Õ µ¶¸³¼º°úÀÇ ¿¬°ü¼º¿¡ ´ëÇÑ ÃÖ±ÙÀÇ ¿¬±¸´Â Èï¹ÌÀÖÀ¸¸ç ±×·¯¹Ç·Î Bcl-2 ´Ü¹é¹ßÇöÀÌ
À¯¹æ¾ÏÀ» Æ÷ÇÔÇÑ »óÇǼ¼Æ÷ À¯·¡ÀÇ Á¾¾ç¿¡ À־ È£¸£¸ó Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀÇ Á¶Àý¿¡ ¸Å¿ì
Áß¿äÇϸ®¶ó »ý°¢µÈ´Ù.
ÃÖ±Ù À¯¹æ¾ÏȯÀÚ¿¡ À־ Bcl-2°¡ È£¸£¸ó ¼ö¿ëüÀÇ Á¸Àç¿Í ¼­·Î »ó½ÂÀÛ¿ëÀÌ ÀÖ´Ù´Â º¸
°í°¡ ÀÖÀ¸¸ç, ÀÓÆÄÀý ÀüÀÌ¿©ºÎ¿Í °ü°è°¡ ÀÖ´Ù´Â º¸°íµµ ÀÖ´Ù. ¶ÇÇÑ Bcl-2 ¹ßÇöÀÇ ¼Ò½ÇÀÌ À¯
¹æ¾Ï ȯÀÚ¿¡ ÀÖ¾î ºÒ·®ÇÑ ¿¹ÈÄ¿Í °ü°è°¡ ÀÖÀ¸¸ç Bcl-2°¡ p53 µî ´Ù¸¥ ¾ÏÀ¯ÀüÀÚ¿Í ¿ªºñ·Ê°ü
°è°¡ ÀÖ´Ù´Â º¸°íµµ ÀÖ´Ù. ÀÌ¿¡ ÀúÀÚµéÀº À¯¹æ¾ÏÀ¸·Î ¼ö¼úÀ» ½ÃÇà¹ÞÀº ȯÀÚ¿¡ À־ ȯÀÚ
ÀÇ ¿¬·É, Æó°æ¿©ºÎ, Á¾¾çÀÇ Å©±â, ¾×¿ÍÀÓÆÄÀý ÀüÀÌ¿©ºÎ, ¿¡½ºÆ®·Î°Õ ¼ö¿ëü(ER) ¹× ÇÁ·Î°Ô½º
Å×·Ð ¼ö¿ëü(PgR) À¯¹«, º´¸®ÇÐÀû Á¶Á÷ºÐÈ­µµ ¹× À¯»çºÐ¿­ Á¤µµ¸¦ Á¶»çÇÏ°í ¶ÇÇÑ Bcl-2 ´Ü
¹éÀÇ ¹ßÇöÀ¯¹«¸¦ Á¶»çÇÏ¿© À̵éÀÇ ¿¹ÈÄÀÎÀڷμ­ÀÇ »ó°ü°ü°è¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

Purpose : There are several well-established prognostic factors to predict the course of
breast cancer. Recently, a new category of genes that control the process of
programmed cell death, also called apoptosis, has been identified. It includes the bcl-2
proto-oncogene which actively blocks apoptosis. The purpose of this retrospective study
is to investigate the relationship between Bcl-2 protein expression in primary breast
cancers and other markers of prognostic value.
Materials and Methods : We analyzed 43 cases of invasive ductal carcinoma of breast
cancer, which were consecutively operated in the period from January 1990 to December
1994. Analysis of Bcl-2 protein, ER and PgR expression was carried out using
immunohistochemistry on the paraffin-embedded tissue section. The following indices
were measured.; size of the tumor, number of axillary metastasis, histological grade,
menopausal status, ER, PgR, and Bcl-2 status.
Results : Expression of the bcl-2 photo-oncogene was found in 28 cases of 43 patients
(65.1%). No relationship could be observed between Bcl-2 status and tumor grade, TNM
staging and menopausal status. A strong positive relationship was demonstrated between
Bcl-2 immunoreactivity and ER status (P=0.001) and PgR status (P=0.014). A favorable
prognostic value was demonstrated for Bcl-2 expression on overall survival (P=0.0427),
but no prognostic value was demonstrated on disease-free survival (P=0.1587).
Conclusion : Our results suggest that the Bcl-2 expression may be a favorable
prognostic marker and its important role may be a modulator of response to adjuvant
therapy in breast cancer.

Å°¿öµå

Bcl-2; Apoptosis; Prognosis; Breast cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS